. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: J Pain. 2019 Dec 11;21(7-8):858–868. doi: 10.1016/j.jpain.2019.11.013

Table 7:

Self-reported neuropathic symptoms are slightly reduced between study visit.

	visit 1 (mean ± SD)	visit 2 (mean ± SD)	p-value
*Neuropathic pain, continuous*
NPSI score (n=22)	37.14 ± 21.60	34.59 ± 21.87	0.187^a
NPQ score (n=21)	0.62 ± 1.10	0.62 ± 1.10	0.951^a
painDETECT score (n=11)	16.45 ± 4.57	14.27 ± 4.52	0.022^*a
*Neuropathic pain, ordinal*
NPQ (n=21), % Yes	76.2%	71.4%	0.011^*b
painDETECT (n=11), % Very likely	36.4%	18.2%	0.126^b
painDETECT (n=11), % Unsure	45.5%	45.5%
*Additional self-report measures, continuous*
Pain Severity (BPI, n=22)	4.56 ± 1.85	4.34 ± 1.89	0.300^a
Pain Interference (BPI, n=22)	2.90 ± 2.48	2.87 ± 2.41	0.907^a
Pain Interference (BPI; median (IQR), n=22)	2.57 (0.82–5.02)	2.07 (0.82–5.18)	0.760^c
Depression (CESD, n=22)	17.45 ± 6.88	17.50 ± 8.11	0.974^a
Pain catastrophizing (PCS, n=10)	24.10 ± 16.22	24.90 ± 15.52	0.625^a
Pain-related anxiety (PASS, n=19)	58.32 ± 36.2	54.11 ± 36.36	0.308^a
Quality of life (LASA, n=19)	6.80 ± 1.41	6.82 ± 1.20	0.927^a

p<0.05.

Statistical tests used include:

^a)

paired t-test

^b)

Fischer’s exact test

^c)

Wilcoxon signed rank test. Fewer subjects completed surveys at visit 2, accounting for reduced numbers with both visit 1 and visit 2 data (subject number in parentheses).